{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-342495","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-08-10T20:30:43+00:00","discovered_at":"2026-08-10T20:33:14.298033+00:00","generated_at":"2026-08-10T20:33:54.281166+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Perspective Therapeutics reports 2Q26 net loss $26.8M; advances VMT-α-NET toward Phase 3","bullets":["Net loss $26.8M ($0.22/share) vs $21.5M ($0.29) in 2Q25; R&D expenses $21.5M, up from $16.6M.","Cash and investments $237M at 6/30/26, up from $145M at 12/31/25; runway into late 2027.","VMT-α-NET: 76 NET patients treated; Phase 3 planned at cumulative 20 mCi dose; site activation targeted year-end 2026.","VMT01: 27 patients; 2 partial responses at 3.0 mCi monotherapy; nivolumab combo cohort progressing.","Appointed Paul Lyne, Ph.D. as Chief Science Officer in July 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-342495","json":"https://secwatch.observer/filing/0001193125-26-342495.json","markdown":"https://secwatch.observer/filing/0001193125-26-342495.md","text":"https://secwatch.observer/filing/0001193125-26-342495.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526342495/0001193125-26-342495-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526342495/catx-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:33:54.281166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}